Roswell Park Cancer Institute

Sorting 10 by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

MonumenTAL-6

A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
  • Bispecific Antibody
  • CD3
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
  • CAR T Cell
  • CELMoD
  • GPRC5D
  • Phase 1

Not yet accepting

GB1211 (Selvigaltin) Combination Therapy

Phase I Trial of GB1211 (Selvigaltin), an Oral Galectin-3 (Gal-3) Inhibitor, Combined With Standard of Care Treatment in Relapsed/Refractory Multiple Myeloma (RRMM)
  • Phase 1

Accepting patients

Belantamab Mafodotin Consolidation

Phase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Positivity After Autologous Stem Cell Transplantation
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 2

Accepting patients

Non-chemotherapeutic Interventions

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
  • Observational Trial

Accepting patients

Isatuximab in Combination With Novel Agents

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol
  • Monoclonal Antibody
  • CD38
  • Randomization
  • Phase 1/2

Accepting patients

P-BCMA-ALLO1

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1
  • Has results

Accepting patients

SX-682

Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
  • CXCR1 Inhibitor
  • CXCR2 Inhibitor
  • Phase 1

Accepting patients

Mezigdomide, Carfilzomib, and Dexamethasone

Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)
  • CELMoD
  • Phase 2